American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
Galera Therapeutics, Inc.
$0.10
+2.75%
OTC: GRTX · 15-min delayed
$149.0MNet income
GRTXOTC
About Galera Therapeutics, Inc.
GALERA THERAPEUTICS INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Net income
- $149.0M
- Total assets
- $7.2M
Source: SEC EDGAR · updated Jun 7, 2026
Multi-year
Revenue & profit trend
FY2019
FY2020
FY2021
FY2022
FY2023
Revenue Net income
FY 2023
Financial statements
Income statement
- Operating income
- -$49.3M
- Income tax
- $0
- Net income
- -$59.1M
Balance sheet
- Total assets
- $26.1M
- Current assets
- $21.6M
- Total liabilities
- $157.3M
- Current liabilities
- $5.0M
- Shareholders’ equity
- -$131.2M
Cash flow
- Operating cash flow
- -$44.8M
- Investing cash flow
- $27.3M
- Financing cash flow
- $31.5M
- Net cash flow
- $13.9M
Statements via Polygon.io (SEC filings)
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Profitable — net income of $149.0M.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Galera Therapeutics, Inc..
Write a review
Newsroom
News about Galera Therapeutics, Inc.
Halper Sadeh LLC is Investigating Whether LEG, AVNS, SEM, GRTX are Obtaining Fair Deals for their Shareholders
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Galera Therapeutics, Inc. (OTCMKTS: GRTX)
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
News & sentiment via Polygon.io
Explore
Browse all →
